Alnylam (ALNY) Pharmaceuticals announced that the Company will present the latest data from its flagship transthyretin amyloidosis franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy, including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the “Hottest Trials and Trial Updates 1” session. Data from the HELIOS-B study supported the recent approvals of AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending approval of vutrisiran for the same indication.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Strong Market Position and Amvuttra’s Impressive Sales Growth Drive Buy Recommendation
- Alnylam Pharma’s Strong Commercial Momentum and Promising Pipeline Justify Buy Rating and $500 Price Target
- Cautious Outlook on Alnylam Pharma Amid Mixed Financial Results and Market Uncertainties
- Alnylam price target raised to $349 from $331 at UBS
- Alnylam Pharma: Strong Market Position and Promising Growth with Buy Rating from Maury Raycroft